Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TIGER

Financiado

Cerrado

Targeted Immunocytokines by CaGing and local Release

Immune therapies have caused a paradigm shift in the treatment of melanoma and leukemias. However, the broad Immune therapies have caused a paradigm shift in the treatment of melanoma and leukemias. However, the broad application... ver más

30/06/2026

ULEI

Presupuesto desconocido

Líder del proyecto

UNIVERSITEIT LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2025-01-01

ERC-2024-POC: ERC PROOF OF CONCEPT GRANTS Objective:ObjectivesThe ERC Proof of Concept Grants aim at facilitating exploration of the commercia...

I+D

Cerrada hace 10 meses

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

ULEI

Lider

Proyectos interesantes

Tumor-Treg-Targeting

Medical Technol...

Data Science

1M€ Cerrado

NEXIM

Medical Technol...

Data Science

71K€ Cerrado

TNT-TUMORS

Medical Technol...

Data Science

2M€ Cerrado

CAR-T-uning

Medical Technol...

Data Science

150K€ Cerrado

SAF2013-42772-R

Medical Technol...

Data Science

121K€ Cerrado

ATECT

Medical Technol...

Data Science

8M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 17 meses Fecha Inicio: 2025-01-01
Fecha Fin: 2026-06-30

Líder del proyecto

UNIVERSITEIT LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Immune therapies have caused a paradigm shift in the treatment of melanoma and leukemias. However, the broad Immune therapies have caused a paradigm shift in the treatment of melanoma and leukemias. However, the broad application of these immune therapies to all cancers has not worked. One of the major reason for this failure is the presence of innate immune suppressive cell types in many tumour types, such as macrophages, NK-, dendritic, and myeloid cells. Tumour selective reactivation of these cells is considered one of the holy grails for the future of immune therapy. Most endeavours in achieving this are severely hampered by the toxicity of innate immune activators: they cause strong off-site-on-target systemic immune activation, which can lead sepsis-like symptoms and death. Developing innate immune activating therapies that are both powerful and safe are therefore key to applying immune therapies across the cancer landscape. As part of my ERC-CoG-Grant I have developed innnate immune activators that are chemically blocked, but that can be reactivated locally to offer. This approach can potentially serve as exactly the safe and potent innate activator required. By targeting the innate activators to the tumour and only activating them once they have accumulated there, we can decouple the therapeutic activity from the systemic toxicity that plagues these approaches. In this proposal, we aim to evaluate the first such a caged innate immune activator in a pre-clinical cancer model. We will validate its potency, pharmacokinetics and caging/decaging behaviour. In addition, we will broaden the scope of the innate activators, antibodies and uncaging chemistries that can be applied. We will also perform market research to determine the optimal tumour-immune activator-antibody combination to take forward into clinical development and begin to take the necessary steps to spin out a company based on this work to bring these non-toxic innate activators to the clinic.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores